Skip header and navigation

Refine By

90 records – page 1 of 9.

Adiponectin gene haplotype is associated with preeclampsia.

https://arctichealth.org/en/permalink/ahliterature170183
Source
Genet Test. 2006;10(1):35-9
Publication Type
Article
Date
2006
Author
Tanja Saarela
Mikko Hiltunen
Seppo Helisalmi
Seppo Heinonen
Markku Laakso
Author Affiliation
Department of Obstetrics and Gynaecology, University of Kuopio, Kuopio, Finland.
Source
Genet Test. 2006;10(1):35-9
Date
2006
Language
English
Publication Type
Article
Keywords
Adiponectin - genetics
Adult
Exons - genetics
Female
Finland
Gene Frequency - genetics
Genetic Predisposition to Disease
Haplotypes - genetics
Humans
Introns - genetics
Polymorphism, Single Nucleotide
Pre-Eclampsia - genetics
Pregnancy
Quantitative Trait Loci - genetics
Abstract
We determined whether the polymorphism of the gene encoding adiponectin contributes to susceptibility to preeclampsia. The study involved 133 Finnish women with preeclampsia and 245 healthy control subjects. All women were genotyped for two single nucleotide polymorphisms (SNPs), SNP45 in exon 2 and SNP276 in intron 2, in the adiponectin gene. Chi2 analysis was used to assess genotype and allele frequency differences between the preeclamptic and control groups. In addition, the pair of loci haplotype analysis, using the expectation-maximization (EM) algorithm, was used to examine the estimated haplotype frequencies of the two SNPs, among the two groups. The TT genotype versus the pooled G genotypes in SNP276 was associated with protection against preeclampsia (p = 0.012) at an odds ratio of 0.27 (95% confidence interval [CI]: 0.09-0.80). Also the genotype and allele frequency distributions of SNP276 differed significantly between the preeclampsia group and the control group (p = 0.035 and p = 0.043, respectively). Single-point genotype and allele distributions in SNP45 of the adiponectin gene were not statistically different between the groups. In the haplotype estimation analysis, the pooled G haplotypes versus the TT haplotype were significantly overrepresented in the preeclampsia group (p = 0.042 +/- 0.005). Polymorphisms of the adiponectin gene show a weak, but statistically significant, haplotype association with susceptibility to preeclampsia in Finnish women.
PubMed ID
16545001 View in PubMed
Less detail

ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study.

https://arctichealth.org/en/permalink/ahliterature147193
Source
Eur J Endocrinol. 2010 Feb;162(2):259-65
Publication Type
Article
Date
Feb-2010
Author
Pirjo Valtonen
Kari Punnonen
Heli Saarelainen
Nonna Heiskanen
Olli T Raitakari
Markus Juonala
Jorma S A Viikari
Georg Alfthan
Mika Kähönen
Reijo Laaksonen
Tiina Lyyra-Laitinen
Tomi Laitinen
Seppo Heinonen
Author Affiliation
Departments of Clinical Chemistry Obstetrics and Gynaecology, Kuopio University Hospital and University of Kuopio, FIN-70210 Kuopio, Finland.
Source
Eur J Endocrinol. 2010 Feb;162(2):259-65
Date
Feb-2010
Language
English
Publication Type
Article
Keywords
Adult
Arginine - analogs & derivatives - blood
Atherosclerosis - epidemiology - metabolism
Brachial Artery - physiology
C-Reactive Protein - metabolism
Contraceptives, Oral - therapeutic use
Creatinine - blood
Estrogens - therapeutic use
Female
Finland - epidemiology
Humans
Menstrual Cycle - metabolism
Progesterone Congeners - therapeutic use
Prospective Studies
Risk factors
Vasodilation - physiology
Young Adult
Abstract
The aim of this study was to evaluate changes in the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) levels during different menstrual cycle phases in young adult women with or without oral contraceptive (OC) use.
The subjects (n=1079) originated from a large population-based, prospective cohort study conducted in Finland. Plasma ADMA, symmetric dimethylarginine (SDMA), L-arginine, C-reactive protein, creatinine, and brachial artery flow-mediated dilatation (FMD) were measured. The use of OCs and menstrual cycle phase were determined from a questionnaire.
In non-OC users, ADMA (P=0.017), L-arginine (P=0.002), and ADMA/SDMA ratio (P
PubMed ID
19934267 View in PubMed
Less detail

Adverse perinatal outcomes associated with moderate or severe maternal anaemia based on parity in Finland during 2006-10.

https://arctichealth.org/en/permalink/ahliterature263229
Source
Paediatr Perinat Epidemiol. 2014 Sep;28(5):372-80
Publication Type
Article
Date
Sep-2014
Author
Sari Räisänen
Vijaya Kancherla
Mika Gissler
Michael R Kramer
Seppo Heinonen
Source
Paediatr Perinat Epidemiol. 2014 Sep;28(5):372-80
Date
Sep-2014
Language
English
Publication Type
Article
Keywords
Adult
Anemia - epidemiology
Female
Finland - epidemiology
Humans
Parity
Pregnancy
Pregnancy Complications, Hematologic - epidemiology
Pregnancy Outcome - epidemiology
Prevalence
Retrospective Studies
Risk factors
Young Adult
Abstract
Anaemia during pregnancy is an important public health problem. We investigated whether the association between maternal anaemia during pregnancy and adverse perinatal outcomes differed between nulliparous and multiparous women.
A retrospective population-based cohort study was conducted using data on all singleton births (n?=?290?662) recorded in the Finnish Medical Birth Register during 2006-10. Maternal anaemia was defined as a maternal haemoglobin level of
PubMed ID
24938307 View in PubMed
Less detail

Anaemia in the first but not in the second or third trimester is a risk factor for low birth weight.

https://arctichealth.org/en/permalink/ahliterature185239
Source
Clin Nutr. 2003 Jun;22(3):271-5
Publication Type
Article
Date
Jun-2003
Author
Henna Hämäläinen
Katja Hakkarainen
Seppo Heinonen
Author Affiliation
Department of Obstetrics and Gynaecology, Kuopio University Hospital, Finland.
Source
Clin Nutr. 2003 Jun;22(3):271-5
Date
Jun-2003
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Anemia - blood - epidemiology
Female
Finland - epidemiology
Hemoglobins - analysis
Humans
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature
Pregnancy - blood
Pregnancy Complications
Pregnancy outcome
Pregnancy Trimester, First - blood
Pregnancy Trimester, Second - blood
Pregnancy Trimester, Third - blood
Retrospective Studies
Risk factors
Abstract
To assess pregnancy outcome in women with anaemia during pregnancy.
The study design involved a retrospective chart review of all women registering for prenatal care in the area of Kuopio University Hospital between 1990 and 2000. A haemoglobin concentration below 100g/l was used as a cutoff for anaemia and affected women (N=597) were stratified by the trimester at which anaemia was diagnosed. Multiple regression analysis was used to compare obstetric outcomes in the study groups and in non-anaemic women (N=22,202).
The frequency of anaemia was 2.6%, with 0.3% occurring in the first trimester. After controlling for confounding factors, anaemia detected in the first trimester was associated with low-birth-weight infants (OR=3.14, 95% CI: 1.35-7.28) whereas the mid- and third-trimester anaemia groups showed no significantly different outcomes when compared with the non-anaemic women. First trimester anaemia was not significantly associated with small birth weight for gestational age (OR=0.98, 95% CI: 0.41-2.17) or with premature delivery
PubMed ID
12765667 View in PubMed
Less detail

Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.

https://arctichealth.org/en/permalink/ahliterature292005
Source
Ann Med. 2017 11; 49(7):593-602
Publication Type
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Date
11-2017
Author
Tiina Jääskeläinen
Sanna Suomalainen-König
Esa Hämäläinen
Kari Pulkki
Jarkko Romppanen
Seppo Heinonen
Hannele Laivuori
Author Affiliation
a Medical and Clinical Genetics , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.
Source
Ann Med. 2017 11; 49(7):593-602
Date
11-2017
Language
English
Publication Type
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Keywords
Adult
Biomarkers - blood
Case-Control Studies
Cross-Sectional Studies
Endoglin - blood
Female
Finland - epidemiology
Humans
Placenta Growth Factor - blood
Pre-Eclampsia - blood - epidemiology
Pregnancy
Pregnancy Trimester, First - blood
Pregnancy Trimester, Second - blood
Retrospective Studies
Risk factors
Risk Reduction Behavior
Smoking - adverse effects - blood - epidemiology
Vascular Endothelial Growth Factor Receptor-1 - blood
Young Adult
Abstract
The biological mechanism by which smoking reduces the risk of pre-eclampsia (PE) is unresolved. We studied serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF) and their ratio, in addition to soluble endoglin (sEng) in early and late pregnancy to ascertain whether these factors are altered in women who smoke.
First trimester serum samples were available from 217 women who later developed PE and 238 women who did not develop PE. Second/third trimester serum samples were available from 174 PE and 54 non-PE women.
PE women who smoked during pregnancy had elevated first trimester concentrations of serum PlGF [geometric mean (95% CI): 39.8 (32.6-48.5) pg/ml, p?=?.001] and reduced sEng concentration [5.0 (4.6-5.6) ng/ml, p?=?.047] compared to PE non-smokers [30.0 (28.1-32.1) pg/ml and 6.1 (5.9-6.4) ng/ml, respectively]. Non-smoking women in the PE group had the highest sFlt-1/PlGF ratio in early and late pregnancy.
The protective effect of smoking in reducing the risk of PE may be due to the early pregnancy change towards pro-angiogenic marker profile. Also, in late pregnancy, smoking exerted effect in sFlt-1/PlGF ratio in PE pregnancies, and may complicate its use as a prognostic and diagnostic marker. Key messages Smoking appears to have angiogenic effects in early pregnancy with reduced sEng concentrations and elevated PlGF concentrations in both normal and PE pregnancies. Throughout pregnancy, smoking exerted effect in PlGF concentration and sFlt-1/PlGF ratio in PE pregnancies, and thus may complicate its use as a prognostic and diagnostic marker.
PubMed ID
28537456 View in PubMed
Less detail

Angiogenic profile in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.

https://arctichealth.org/en/permalink/ahliterature297906
Source
Pregnancy Hypertens. 2018 Oct; 14:252-259
Publication Type
Journal Article
Date
Oct-2018
Author
Tiina Jääskeläinen
Seppo Heinonen
Esa Hämäläinen
Kari Pulkki
Jarkko Romppanen
Hannele Laivuori
Author Affiliation
Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: tiina.j.jaaskelainen@helsinki.fi.
Source
Pregnancy Hypertens. 2018 Oct; 14:252-259
Date
Oct-2018
Language
English
Publication Type
Journal Article
Keywords
Adult
Biomarkers - blood
Case-Control Studies
Comorbidity
Cross-Sectional Studies
Endoglin - blood
Female
Finland - epidemiology
Humans
Parity
Placenta Growth Factor - blood
Pre-Eclampsia - blood - diagnosis - epidemiology
Predictive value of tests
Pregnancy
Prospective Studies
Vascular Endothelial Growth Factor Receptor-1 - blood
Abstract
To study first and second/third trimester levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF) and soluble endoglin (sEng) in FINNPEC case-control cohort. The participants were further divided into subgroups based on parity and onset of the disease. Recommended cut-off values in aid of pre-eclampsia (PE) prediction and diagnosis were also tested.
First trimester serum samples were available from 221 women who later developed PE and 239 women who did not develop PE. Second/third trimester serum samples were available from 175 PE and 55 non-PE women. sFlt-1 and PlGF were measured electro-chemiluminescence immunoassays and sEng by ELISA.
In all timepoints PlGF, endoglin and the sFlt-1/PlGF ratio were increased in the PE group compared to the non-PE group. The serum concentrations of sFlt-1 were increased only at second/third trimester in PE women. Higher concentrations of s-Flt1, endoglin and higher sFlt/PlGF ratio were found at the third trimester in primiparous women compared to multiparous women. Primiparous PE women also had lower concentrations of PlGF at the third trimester. The proportion of women exceeding all cut-offs of the sFlt-1/PlGF ratio (=33, =38, =85 and?=110) was greater in the PE group, but there were also pre-eclamptic women who met rule-out cut-off or did not meet rule-in cut-off.
Primiparous pregnancies have more anti-angiogenic profile during second/third trimester compared with multiparous pregnancies. Our findings also suggest that certain maternal characteristics, e.g. BMI, smoking and pre-existing diseases, should be taken into account when different sFlt-1/PlGF ratio cut-offs are utilized.
PubMed ID
29803331 View in PubMed
Less detail

Association of risk variants for type 2 diabetes and hyperglycemia with gestational diabetes.

https://arctichealth.org/en/permalink/ahliterature113138
Source
Eur J Endocrinol. 2013 Sep;169(3):291-7
Publication Type
Article
Date
Sep-2013
Author
Hanna Huopio
Henna Cederberg
Jagadish Vangipurapu
Heidi Hakkarainen
Mirja Pääkkönen
Teemu Kuulasmaa
Seppo Heinonen
Markku Laakso
Author Affiliation
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Source
Eur J Endocrinol. 2013 Sep;169(3):291-7
Date
Sep-2013
Language
English
Publication Type
Article
Keywords
Adult
Case-Control Studies
Diabetes Mellitus, Type 2 - genetics - metabolism
Diabetes, Gestational - blood - genetics - metabolism
Down-Regulation
Female
Finland
Follow-Up Studies
Genetic Association Studies
Genetic Predisposition to Disease
Glucose Tolerance Test
Hospitals, University
Humans
Hyperglycemia - blood - genetics - metabolism
Insulin - blood - secretion
Insulin-Secreting Cells - secretion
Middle Aged
Polymorphism, Single Nucleotide
Pregnancy
Receptor, Melatonin, MT1 - genetics - metabolism
Abstract
The aim of this study was to investigate the association of risk variants for type 2 diabetes (T2D) and hyperglycemia with gestational diabetes (GDM).
Five hundred and thirty-three Finnish women who were diagnosed with GDM and 407 controls with normal glucose tolerance during the pregnancy were genotyped for 69 single-nucleotide polymorphisms (SNPs) which have been previously verified as susceptibility risk variants for T2D and hyperglycemia. All participants underwent an oral glucose tolerance test at the follow-up study after the index pregnancy.
Risk variants rs10830963 and rs1387153 of MTNR1B were significantly associated with GDM (odds ratio (OR)=1.62 (95% CI 1.34-1.96), P=4.5 × 10?7 and 1.38 (1.14-1.66), P=7.6 × 10?4 respectively). Both SNPs of MTNR1B were also significantly associated with elevated fasting glucose level and reduced insulin secretion at follow-up. Additionally, risk variants rs9939609 of FTO, rs2796441 of TLE1, rs560887 of G6PC2, rs780094 of GCKR, rs7903146 of TCF7L2 and rs11708067 of ADCY5 showed nominally significant associations with GDM (OR range from 1.25 to 1.30).
Our study suggests that GDM and T2D share a similar genetic background. Our findings also provide further evidence that risk variants of MTNR1B are associated with GDM by increasing fasting plasma glucose and decreasing insulin secretion.
PubMed ID
23761423 View in PubMed
Less detail

Associations between two single nucleotide polymorphisms in the adiponectin gene and polycystic ovary syndrome.

https://arctichealth.org/en/permalink/ahliterature171619
Source
Gynecol Endocrinol. 2005 Sep;21(3):165-9
Publication Type
Article
Date
Sep-2005
Author
Seppo Heinonen
Seija Korhonen
Seppo Helisalmi
Riitta Koivunen
Juha Tapanainen
Maritta Hippeläinen
Markku Laakso
Author Affiliation
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland. seppo.heinonen@kuh.fi
Source
Gynecol Endocrinol. 2005 Sep;21(3):165-9
Date
Sep-2005
Language
English
Publication Type
Article
Keywords
Adiponectin - genetics
Case-Control Studies
DNA - analysis
DNA Primers
European Continental Ancestry Group - genetics
Female
Finland
Humans
Polycystic Ovary Syndrome - genetics
Polymerase Chain Reaction
Polymorphism, Single Nucleotide - genetics
Abstract
In the present study we determined whether genetic variability in the gene encoding adiponectin is associated with polycystic ovary syndrome (PCOS). Altogether 143 Caucasian women with PCOS and 245 healthy controls were genotyped for two single nucleotide polymorphisms (SNPs) in exon 2 and intron 2 in the adiponectin gene. Single-point analysis was expanded to pair-of-loci haplotype analysis to examine the estimated haplotype frequencies of the two SNPs, of unknown phase, in the PCOS and control groups. Estimated haplotype frequencies were assessed using the maximum-likelihood method, employing an expectation-maximization algorithm. A significantly different allele distribution in intron 2 SNP was observed between the groups, with the T allele being significantly reduced in the PCOS group (25.9%) compared with the control group (32.7%) ( p = 0.047), at an odds ratio of 0.72 (95% confidence interval 0.52-0.99). Otherwise, the allele and genotype distributions in either SNP were not statistically different between the groups. In haplotype estimation analysis, there was a lower frequency of the haplotype T-T in the PCOS group (25.9%) than in the control group (32.7%) ( p = 0.058). We conclude that polymorphisms of the adiponectin gene may be implicated in individual susceptibility to PCOS.
PubMed ID
16335909 View in PubMed
Less detail

A BRCA2 mutation, 4088insA, in a Finnish breast and ovarian cancer family associated with favourable clinical course.

https://arctichealth.org/en/permalink/ahliterature159199
Source
Anticancer Res. 2007 Nov-Dec;27(6C):4295-300
Publication Type
Article
Author
Jaana M Hartikainen
Arto Mannermaa
Seppo Heinonen
Veli-Matti Kosma
Vesa Kataja
Author Affiliation
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Finland. jaana.hartikainen@uku.fi
Source
Anticancer Res. 2007 Nov-Dec;27(6C):4295-300
Language
English
Publication Type
Article
Keywords
Base Sequence
Breast Neoplasms - genetics
DNA Mutational Analysis
Female
Finland
Genes, BRCA2
Genetic Predisposition to Disease
Haplotypes
Heterozygote
Humans
Mutation
Ovarian Neoplasms - genetics
Pedigree
Prognosis
Treatment Outcome
Abstract
Mutations in the BRCA1/2 genes confer a high risk for breast and ovarian cancer, with usually adverse clinical characteristics. The clinical course and response to treatment in mutation carriers have been reported infrequently and are assumed to be worse than in sporadic breast cancer.
Eleven members of an Eastern Finnish family with multiple cases of breast and ovarian cancers were screened for BRCA1/2 mutations using protein truncation test (PTT), conformation-sensitive gel electrophoresis (CSGE) and sequencing.
Five of the six BRCA2 4088insA mutation carriers were affected. Mutation-positive breast/ovarian cancer patients had an excellent response to treatment even when prognosis as assessed by classical factors was poor.
The 4088insA mutation appears to be associated with a favourable clinical course of breast and ovarian cancer, providing an informative example on the role of an individual mutation in assessing the prognosis for mutation carriers. Our results encourage more research on the effects of an individual mutation on clinical characteristics, response to treatment and outcome.
PubMed ID
18214034 View in PubMed
Less detail

The burden of childhood asthma and late preterm and early term births.

https://arctichealth.org/en/permalink/ahliterature106251
Source
J Pediatr. 2014 Feb;164(2):295-9.e1
Publication Type
Article
Date
Feb-2014
Author
Maijakaisa Harju
Leea Keski-Nisula
Leena Georgiadis
Sari Räisänen
Mika Gissler
Seppo Heinonen
Author Affiliation
Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland. Electronic address: maijakaisa.harju@kuh.fi.
Source
J Pediatr. 2014 Feb;164(2):295-9.e1
Date
Feb-2014
Language
English
Publication Type
Article
Keywords
Adolescent
Child
Child, Preschool
Female
Finland - epidemiology
Follow-Up Studies
Gestational Age
Humans
Infant
Infant, Low Birth Weight
Infant, Newborn
Infant, Premature, Diseases - epidemiology
Male
Morbidity - trends
Pregnancy
Premature Birth - epidemiology
Registries
Retrospective Studies
Risk Assessment - methods
Risk factors
Socioeconomic Factors
Young Adult
Abstract
To evaluate the association between gestational age at birth and the risk of subsequent development of asthma.
We conducted a retrospective observational hospital-based birth case-control study in a university-based obstetrics and gynecology department in Finland. A total of 44,173 women delivering between 1989 and 2008 were linked with the social insurance register to identify asthma reimbursements for their offspring (n = 2661). Pregnancy factors were recorded during pregnancy. Infants were categorized as moderately preterm (= 32 weeks), late preterm (33-36 weeks), early term (37-38 weeks), term (39-40 weeks), or late term and postterm (= 41 weeks). The main outcome measure was asthma among the infants.
Children born moderately preterm (= 32 weeks gestation) had a significantly increased risk of asthma (aOR, 3.9; 95% CI, 3.2-4.8). The risk of asthma was also increased in those born late preterm (aOR, 1.7; 95% CI, 1.4-2.0) and early term (aOR, 1.2; 95% CI, 1.1-1.4). In contrast, delivery at 41 weeks or later seemed to decrease the risk of asthma (aOR, 0.9; 95% CI, 0.8-1.0). The burden of asthma associated with preterm birth was associated mainly with early term infants, in whom 108 extra cases of asthma were observed.
Even though the individual risk of asthma was inversely correlated with gestational age at birth, the overall burden brought about by delivery before term was associated with late preterm and early term deliveries. Furthermore, delivery after term was protective against asthma.
PubMed ID
24210922 View in PubMed
Less detail

90 records – page 1 of 9.